Lu TX, et al. - Researchers examined diffuse large B-cell lymphoma (DLBCL) patients to determine the prognostic ability of baseline aspartic transaminase (AST) in these patients. In 179 DLBCL patients treated from 2006 to 2016, they examined the link between AST and clinical features. Treatment with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) or R-CHOP-like chemotherapy was received by all enrolled patients. They evaluated the influence of AST on survival by performing log-rank test, univariable analysis, and subgroup analysis. For predicting prognosis, AST 33.3 U/L was determined to be the optimal threshold value. In DLBCL patients treated with R-CHOP or similar chemotherapy regimens, a link was evident between a pretreatment AST level and overall survival. In DLBCL patients, a dismal outcome might be reliably predicted by a high pretreatment AST level. For risk evaluation in patients with DLBCL, serum AST levels may possibly be used as an easily determinable, inexpensive biomarker.